Insulin Sensitivity in Multiple Pathways Is Differently Affected During Zidovudine/Lamivudine-Containing Compared With NRTI-Sparing Combination Antiretroviral Therapy

Objective:The extent and manner by which HIV nucleoside reverse transcriptase inhibitors contribute to insulin resistance is unclear. We evaluated the effect of zidovudine/lamivudine (ZDV/3TC) on glucose metabolism. Methods:combination antiretroviral therapy-naive men were randomized to lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) + ZDV/3TC or LPV/r (533/133 mg twice a day) + nevirapine (NVP). Computerized tomography, dual-energy X-ray absorptiometry scans, and hyperinsulinemic euglycemic clamps using stable isotopes were performed before and after 3, 12, and 24 months of combination antiretroviral therapy. Results:Insulin-stimulated peripheral glucose disposal decreased by 25% after 3 months in patients on zidovudine/lamivudine/lopinavir/ritonavir (ZDV/3TC/LPV/r) (P < 0.001) and this decreased rate persisted thereafter, followed by a transient decrease in insulin-mediated inhibition of lipolysis. In the nevirapine/lopinavir/ritonavir (NVP/LPV/r) group, hepatic insulin sensitivity had improved compared with baseline after 24 months. After the initial 3 months, limb fat decreased in the ZDV/3TC/LPV/r arm up to 24 months [−849 ± 345 g (P = 0.017)], and visceral adipose tissue increased over 2 years [+36.2 ± 13.3 cm2 (P = 0.009)]. In the NVP/LPV/r group, a generalized increase in fat mass was observed. Conclusions:Treatment with ZDV/3TC/LPV/r versus NVP/LPV/r differentially affects glucose and lipid metabolism. The ZDV/3TC/LPV/r regimen induced peripheral insulin resistance, a transient increase in basal lipolysis and a transient decrease in insulin-mediated inhibition of lipolysis, whereas hepatic insulin sensitivity improved with the NVP/LPV/r regimen.

[1]  S. Weise,et al.  Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients , 2009, AIDS.

[2]  S. Cole,et al.  Antiretroviral Therapy Exposure and Insulin Resistance in the Women's Interagency HIV Study , 2008, Journal of acquired immune deficiency syndromes.

[3]  P. Reiss,et al.  Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy , 2008, AIDS.

[4]  S. Cole,et al.  Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study , 2007, AIDS.

[5]  M. Noor,et al.  The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: Cellular mechanisms and clinical implications , 2007, Current HIV/AIDS reports.

[6]  W. Frontera,et al.  Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. , 2007, American journal of physiology. Endocrinology and metabolism.

[7]  J. Capeau,et al.  Some HIV Antiretrovirals Increase Oxidative Stress and Alter Chemokine, Cytokine or Adiponectin Production in Human Adipocytes and Macrophages , 2007, Antiviral therapy.

[8]  K. Petersen,et al.  Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links With Mitochondrial Dysfunction , 2006, Diabetes.

[9]  R. Considine,et al.  Insulin sensitivity is preserved despite disrupted endothelial function. , 2006, American journal of physiology. Endocrinology and metabolism.

[10]  R. Parker,et al.  Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically , 2006, AIDS.

[11]  M. Schambelan,et al.  Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  S. Weise,et al.  Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. , 2006, American journal of physiology. Endocrinology and metabolism.

[13]  Francesc Villarroya,et al.  Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. , 2005, Trends in pharmacological sciences.

[14]  P. Hruz,et al.  A Structural Basis for the Acute Effects of HIV Protease Inhibitors on GLUT4 Intrinsic Activity* , 2004, Journal of Biological Chemistry.

[15]  Madhu N. Rao,et al.  The effects of HIV protease inhibitors on carbohydrate and lipid metabolism , 2004, Current infectious disease reports.

[16]  R. Parker,et al.  The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults , 2004, AIDS.

[17]  M. Schambelan,et al.  HIV protease inhibitors increase adiponectin levels in HIV-negative men. , 2004, Journal of acquired immune deficiency syndromes.

[18]  M. Schambelan,et al.  The metabolic effects of lopinavir/ritonavir in HIV-negative men , 2004, AIDS.

[19]  H. Pownall,et al.  Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of ‘systemic steatosis’ , 2004, Current opinion in lipidology.

[20]  C. Pond,et al.  Site-specific differences in the action of NRTI drugs on adipose tissue incubated in vitro with lymphoid cells, and their interaction with dietary lipids. , 2003, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[21]  S. Welle,et al.  Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. , 2003, Diabetes.

[22]  C. Mantzoros,et al.  Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  P. Scherer,et al.  Adiponectin and Leptin Levels in HIV‐Infected Subjects With Insulin Resistance and Body Fat Redistribution , 2002, Journal of acquired immune deficiency syndromes.

[24]  F. van Leth,et al.  Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. , 2002, Journal of Clinical Endocrinology and Metabolism.

[25]  M. Schambelan,et al.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study , 2002, AIDS.

[26]  P. Reiss,et al.  Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways , 2001, AIDS.

[27]  P. Scherer,et al.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.

[28]  I. Harman-boehm,et al.  The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. , 2001, Diabetes.

[29]  E. Furfine,et al.  HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. , 2000, Antiviral research.

[30]  P. Hruz,et al.  The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy* , 2000, The Journal of Biological Chemistry.

[31]  J. M. Aerts,et al.  Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance. , 2007, The Journal of clinical endocrinology and metabolism.